Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Case Reports
. 2017 May 31;15(2):184-186.
doi: 10.9758/cpn.2017.15.2.184.

Bilateral Pretibial Edema Associated with Paliperidone Palmitate Long-acting Injectable: A Case Report

Erdinc Cicek  1 , Ismet Esra Cicek  2 , Faruk Uguz  3
Affiliations
Case Reports

Bilateral Pretibial Edema Associated with Paliperidone Palmitate Long-acting Injectable: A Case Report

Erdinc Cicek et al. Clin Psychopharmacol Neurosci. .

Abstract

Peripheral edema is observed as an adverse effect of the usage of antipsychotics in the literature. This case report describes a 36-year-old female patient with the diagnosis of paranoid schizophrenia who presented with pretibial edema following initiation of long-acting injectable paliperidone palmitate. Pretibial edema developed within the second week of treatment and completely disappeared after its discontinuation.

Keywords: Edema; Long-acting injectable; Paliperidone palmitate.

PubMed Disclaimer

Similar articles

See all similar articles

Cited by

References

    1. Gilday E, Nasrallah HA. Clinical pharmacology of paliperidone palmitate a parenteral long-acting formulation for the treatment of schizophrenia. Rev Recent Clin Trials. 2012;7:2–9. doi: 10.2174/157488712799363307. - DOI - PubMed
    1. Taylor D. Psychopharmacology and adverse effects of anti-psychotic long-acting injections: a review. Br J Psychiatry Suppl. 2009;52:S13–S19. doi: 10.1192/bjp.195.52.s13. - DOI - PubMed
    1. Gopal S, Gassmann-Mayer C, Palumbo J, Samtani MN, Shiwach R, Alphs L. Practical guidance for dosing and switching paliperidone palmitate treatment in patients with schizophrenia. Curr Med Res Opin. 2010;26:377–387. doi: 10.1185/03007990903482772. - DOI - PubMed
    1. Chwieduk CM, Keating GM. Paliperidone extended release: a review of its use in the management of schizophrenia. Drugs. 2010;70:1295–1317. doi: 10.2165/11204840-000000000-00000. - DOI - PubMed
    1. Samtani MN, Gopal S, Gassmann-Mayer C, Alphs L, Palumbo JM. Dosing and switching strategies for paliperidone palmitate: based on population pharmacokinetic modelling and clinical trial data. CNS Drugs. 2011;25:829–845. - PubMed

Publication types